Lista skapad 2015-06-26
2014
Arving C, Brandberg Y, Feldman I, Johansson B, Glimelius B: Cost-utility analysis of individual psychosocial support interventions for breast cancer patients in a randomized controlled study. Psychooncology 2014, 23(3):251-258.
Bergenmar M, Johansson H, Wilking N, Hatschek T, Brandberg Y: Audio-recorded information to patients considering participation in cancer clinical trials – a randomized study. Acta Oncol 2014, 53(9):1197-1204.
Boix-Perales H, Borregaard J, Jensen KB, Ersboll J, Galluzzo S, Giuliani R, Ciceroni C, Melchiorri D, Salmonson T, Bergh J et al: The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2014, 19(7):766-773.
Bonnefoi H, Litiere S, Piccart M, MacGrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Moldovan C et al: Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2014, 25(6):1128-1136.
Butt S, Butt T, Jirstrom K, Hartman L, Amini RM, Zhou W, Warnberg F, Borgquist S: The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy. Annals of surgical oncology 2014, 21(9):2911-2919.
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL et al: ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014, 23(5):489-502.
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL et al: ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)dagger. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2014, 25(10):1871-1888.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P et al: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014, 384(9938):164-172.
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G et al: Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014, 383(9922):1041-1048.
Einarsdottir BO, Bagge RO, Bhadury J, Jespersen H, Mattsson J, Nilsson LM, Truve K, Lopez MD, Naredi P, Nilsson O et al: Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. Oncotarget 2014, 5(20):9609-9618.
Falato C, Lorent J, Tani E, Karlsson E, Wright PK, Bergh J, Foukakis T: Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer. Breast Cancer Res Treat 2014, 147(2):407-414.
Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, Riis ML, Haakensen VD, Warnberg F, Naume B et al: Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome Biol 2014, 15(8):435.
Foukakis T, Lovrot J, Bergh J: Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med 2014, 371(1):84-85.
Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Strom CE, Svensson LM, Schultz N, Lundback T, Einarsdottir BO et al: MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature 2014, 508(7495):215-221.
Hajiebrahimi M, Cnattingius S, Lambe M, Hsieh CC, Ahlgren J, Adolfsson J, Bahmanyar S: Birth size in the most recent pregnancy and maternal mortality in premenopausal breast cancer by tumor characteristics. Breast Cancer Res Treat 2014, 145(2):471-480.
Jansson S, Bendahl PO, Grabau DA, Falck AK, Ferno M, Aaltonen K, Ryden L: The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRalpha, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. PLoS One 2014, 9(7):e102176.
Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Saarni O, Helle L et al: Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncol 2014, 53(2):186-194.
Karlsson E, Appelgren J, Solterbeck A, Bergenheim M, Alvariza V, Bergh J: Breast cancer during follow-up and progression – A population based cohort on new cancers and changed biology. Eur J Cancer 2014, 50(17):2916-2924.
Karlsson E, Sandelin K, Appelgren J, Zhou W, Jirstrom K, Bergh J, Warnberg F: Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events. Eur J Cancer 2014, 50(3):517-524.
Kessler L, Falato C, Margolin S, Bergh J, Foukakis T: A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden. Acta Oncol 2015, 54(4):522-529.
Kimbung S, Kovacs A, Bendahl PO, Malmstrom P, Ferno M, Hatschek T, Hedenfalk I: Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Mol Oncol 2014, 8(1):119-128.
Klevebring D, Rosin G, Ma R, Lindberg J, Czene K, Kere J, Fredriksson I, Bergh J, Hartman J:
Sequencing of breast cancer stem cell populations indicates a dynamic conversion between
differentiation states in vivo. Breast Cancer Res 2014, 16(4):R72.
Lawler M, Le Chevalier T, Murphy MJ, Jr., Banks I, Conte P, De Lorenzo F, Meunier F, Pinedo HM,
Selby P, Armand JP et al: A catalyst for change: the European cancer Patient’s Bill of Rights.
Oncologist 2014, 19(3):217-224.
Li J, Holm J, Bergh J, Eriksson M, Darabi H, Lindstrom LS, Tornberg S, Hall P, Czene K: Breast cancer
genetic risk profile is differentially associated with interval and screen-detected breast cancers. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015, 26(3):517-522.
Liu Y, Zhou R, Baumbusch LO, Tsavachidis S, Brewster AM, Do KA, Sahin A, Hortobagyi GN, Taube JH, Mani SA et al: Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat 2014, 143(1):189-201.
Lundh MH, Lampic C, Nordin K, Ahlgren J, Bergkvist L, Lambe M, Berglund A, Johansson B: Sickness absence and disability pension following breast cancer – A population-based matched cohort study. Breast 2014, 23(6):844-851.
Ma R, Fredriksson I, Karthik GM, Winn G, Darai-Ramqvist E, Bergh J, Hartman J: Superficial scrapings from breast tumors is a source for biobanking and research purposes. Lab Invest 2014, 94(7):796-805.
McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T et al: Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20- year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014, 383(9935):2127-2135.
Narbe U, Bendahl PO, Grabau D, Ryden L, Ingvar C, Ferno M: Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor. Springerplus 2014, 3:70.
Rissanen R, Arving C, Ahlgren J, Nordin K: Group versus individual stress management intervention in breast cancer patients for fatigue and emotional reactivity: a randomised intervention study. Acta Oncol 2014, 53(9):1221-1229.
Romero Q, Bendahl PO, Ferno M, Grabau D, Borgquist S: A novel model for Ki67 assessment in breast cancer. Diagn Pathol 2014, 9:118.
Rosin G, de Boniface J, Karthik GM, Frisell J, Bergh J, Hartman J: Oestrogen receptors beta1 and betacx have divergent roles in breast cancer survival and lymph node metastasis. British journal of cancer 2014, 111(5):918-926.
Simonsson M, Markkula A, Bendahl PO, Rose C, Ingvar C, Jernstrom H: Pre- and postoperative alcohol consumption in breast cancer patients: impact on early events. Springerplus 2014, 3:261.
Sjostrom M, Hartman L, Grabau D, Fornander T, Malmstrom P, Nordenskjold B, Sgroi DC, Skoog L, Stal O, Leeb-Lundberg LM et al: Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer. Breast Cancer Res Treat 2014, 145(1):61-71.
Stalhammar G, Rosin G, Fredriksson I, Bergh J, Hartman J: Low concordance of biomarkers in histopathological and cytological material from breast cancer. Histopathology 2014, 64(7):971-980.
Tobin NP, Harrell JC, Lovrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M et al: Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015, 26(1):81-88.
Tobin NP, Lindstrom LS, Carlson JW, Bjohle J, Bergh J, Wennmalm K: Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients. Mol Oncol 2014, 8(3):741-752.
Unukovych D, Johansson H, Johansson E, Arver B, Liljegren A, Brandberg Y: Physical therapy after prophylactic mastectomy with breast reconstruction: a prospective randomized study. Breast 2014, 23(4):357-363.
von Stedingk H, Xie H, Hatschek T, Foukakis T, Ryden A, Bergh J, Rydberg P: Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide. Cancer Chemother Pharmacol 2014, 74(3):549-558.
Wang J, Tsouko E, Jonsson P, Bergh J, Hartman J, Aydogdu E, Williams C: miR-206 inhibits cell migration through direct targeting of the actin-binding protein coronin 1C in triple-negative breast cancer. Mol Oncol 2014, 8(8):1690-1702.
Warnberg F, Garmo H, Emdin S, Hedberg V, Adwall L, Sandelin K, Ringberg A, Karlsson P, Arnesson LG, Anderson H et al: Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol 2014, 32(32):3613-3618.
Winters ZE, Balta V, Thomson HJ, Brandberg Y, Oberguggenberger A, Sinove Y, Unukovych D, Nava M, Sandelin K, Johansson H et al: Phase III development of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire module for women undergoing breast reconstruction. The British journal of surgery 2014, 101(4):371-382.
Zhou W, Sollie T, Tot T, Pinder SE, Amini RM, Blomqvist C, Fjallskog ML, Christensson G, Abdsaleh S, Warnberg F: Breast cancer with neoductgenesis: histopathological criteria and its correlation with mammographic and tumour features. International journal of breast cancer 2014, 2014:581706.
2013
Adwall L, Liljegren G, Olsson L, Wärnberg F. Antibiotic prophylaxis in breast surgery? Yes, but not for everyone. Quality data from the Uppsala county council provides draft for guideline. Lakartidningen. 2013 Jan 30-Feb 5;110(5):213-215.
Alkner S, Bendahl P, Grabau D, Malmstrom P, Ferno M, Ryden L: The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013, 24(5):1244-1252.
Allemani C, Sant M, Weir HK, Richardson LC, Baili P, Storm H, Siesling S, Torrella-Ramos A, Voogd AC, Aareleid T et al: Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer 2013, 132(5):1170-1181.
Andersson Y, Frisell J, Sylvan M, de Boniface J, Bergkvist L: Causes of false-negative sentinel node biopsy in patients with breast cancer. The British journal of surgery 2013, 100(6):775-783.
Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J et al: Health-related quality of life with adjuvant docetaxel- and trastuzumab- based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist 2013, 18(7):812-818.
Bjarnadottir O, Romero Q, Bendahl PO, Jirstrom K, Ryden L, Loman N, Uhlen M, Johannesson H, Rose C, Grabau D et al: Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat 2013, 138(2):499-508.
Bjöhle J, Bergqvist J, Gronowitz JS, Johansson H, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Söderberg M, Sundquist M, Walz TM, Fernö M, Bergh J, Hatschek T. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer Res Treat. 2013 Jun;139(3):751-8.
Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskjold B, Stal O:
Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen
treatment benefit. Breast Cancer Res Treat 2013, 137(2):397-406.
Broselid S, Cheng B, Sjostrom M, Lovgren K, Klug-De Santiago HL, Belting M, Jirstrom K, Malmstrom P,
Olde B, Bendahl PO et al: G protein-coupled estrogen receptor is apoptotic and correlates with increased distant disease-free survival of estrogen receptor-positive breast cancer patients. Clin Cancer Res 2013, 19(7):1681-1692.
Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J et al: Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 2013, 9(3):e1003212.
Crona J, Granberg D, Norlén O, Wärnberg F, Stålberg P, Hellman P, Björklund P. Metastases from Neuroendocrine Tumors to the Breast Are More Common than Previously Thought. A Diagnostic Pitfall? World J Surg. 2013 Jul;37(7):1701-6.
Domanski AM, Monsef N, Domanski HA, Grabau D, Ferno M: Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients. Cytopathology : official journal of the British Society for Clinical Cytology 2013, 24(1):21-25.
Fahlen M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz E: Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 2013, 49(1):52-59.
Falck AK, Bendahl PO, Chebil G, Olsson H, Ferno M, Ryden L: Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years’ follow-up. Breast Cancer Res Treat 2013, 140(1):93-104.
Falck AK, Ferno M, Bendahl PO, Ryden L: St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases–aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial. BMC Cancer 2013, 13:558.
Fohlin H, Perez-Tenorio G, Fornander T, Skoog L, Nordenskjold B, Carstensen J, Stal O: Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer. Eur J Cancer 2013, 49(6):1196-1204.
Fornvik D, Andersson I, Dustler M, Ehrnstrom R, Ryden L, Tingberg A, Zackrisson S, Aaltonen K: No evidence for shedding of circulating tumor cells to the peripheral venous blood as a result of mammographic breast compression. Breast Cancer Res Treat 2013, 141(2):187-195.
Gahm J, Hansson P, Brandberg Y, Wickman M: Breast sensibility after bilateral risk-reducing mastectomy and immediate breast reconstruction: a prospective study. Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2013, 66(11):1521-1527.
Goldhirsch A, Winer E.P, Coates A.S, Gelber R.D, Piccart-Gebhart M, Thürlimann B, Senn H.-J and Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology 24;9:2206-2223, 2013.
Gothlin Eremo A, Wegman P, Stal O, Nordenskjold B, Fornander T, Wingren S: Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients. Oncol Rep 2013, 29(4):1467-1474.
Grabau D, Dihge L, Ferno M, Ingvar C, Ryden L: Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade’s experience from a single institution. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2013, 39(6):601- 607.
Grabau DA, Bendahl PO, Ryden L, Stal O, Ferno M: The prevalence of immunohistochemically determined oestrogen receptor positivity in primary breast cancer is dependent on the choice of antibody and method of heat-induced epitope retrieval – prognostic implications? Acta Oncol 2013, 52(8):1657-1666.
Hajiebrahimi MH, Bahmanyar S, Lambe M, Adolfsson J, Fornander T, Warnberg F, Cnattingius S: Placental weight and mortality in premenopausal breast cancer by tumor characteristics. Breast Cancer Res Treat 2013, 137(1):297-305.
Iggo R, Rudewicz J, Monceau E, Sevenet N, Bergh J, Sjöblom T and Bonnefoi H. Validation of a yeast functional assay for p53 mutations using clonal sequencing. J Pathol 231:441-448, 2013.
Jiao X, Hooper SD, Djureinovic T, Larsson C, Wärnberg F, Tellgren-Roth C, Botling J, Sjöblom T. Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing. BMC Genomics. 2013 Mar 12;14:165.
Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Saarni O, Helle L, Villman K, Nyandoto P, Nilsson G, Leinonen M, Kataja V, Bono P, Lindman H. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncol. 2014 Feb;53(2):186-94. doi: 10.3109/0284186X.2013.820840. Epub 2013 Aug 19.
Kalderstam J, Eden P, Bendahl PO, Strand C, Ferno M, Ohlsson M: Training artificial neural networks directly on the concordance index for censored data using genetic algorithms. Artif Intell Med 2013, 58(2):125-132.
Karlsson E, Perez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, Sgroi DC, Nordenskjold B, Hallbeck AL, Stal O: The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res 2013, 15(5):R96.
Kaufmann M, von Minckwitz G, Bergh J, Conte P-F, Darby S, Eiermann W, Howell A, Kiechle M, Mauri D, Senn H-J, Viale G, Loibl S. Breakthroughs in research and treatment of early breast cancer: an overwiew of the last three decades. Arch Gynecol Obstet 288:1203-1212, 2013.
Klajic J, Fleischer T, Dejeux E, Edvardsen H, Warnberg F, Bukholm I, Lønning PE, Solvang H, Børresen- Dale AL, Tost J, Kristensen VN. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer. 2013 Oct 5;13(1):456.
Klintman M, Nilsson F, Bendahl PO, Ferno M, Liljegren G, Emdin S, Malmstrom P: A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013, 24(9):2284-2291.
Klintman M, Strand C, Ahlin C, Beglerbegovic S, Fjallskog ML, Grabau D, Gudlaugsson E, Janssen EA, Lovgren K, Skaland I et al: The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer. PLoS One 2013, 8(12):e81902.
Linderholm BK, Lidbrink E, Tallroth E, Einbeigi Z, Svensson H, von Wachenfeldt A, Norberg B, Carlsson L, Olsson ME, Bergh J, Wilking N, Hatschek T. Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel. Breast. 2013 Dec;22(6):1142-7
Lundberg J, Thorarinsson A, Karlsson P, Ringberg A, Frisell J, Hatschek T, Kallstrom AC, Elander A:
When Is the Deep Inferior Epigastric Artery Flap Indicated for Breast Reconstruction in
Patients not Treated With Radiotherapy? Ann Plast Surg 2013.
Lundh MH, Lampic C, Nordin K, Ahlgren J, Bergkvist L, Lambe M, Berglund A, Johansson B: Changes in
health-related quality of life by occupational status among women diagnosed with breast
cancer-a population-based cohort study. Psychooncology 2013.
Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A,
Fornander T et al: Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013, 14(1):72-80.
Milosevic J and Klinge J*, Borg A-L, Foukakis T, Bergh J and Tobin NP. Clinical instability of breast cancer markers is reflected in long term in vitro estrogen deprivation studies. BMC Cancer 11;13:473, 2013
Mohammadhossein Hajiebrahimi, Sven Cnattingius, Mats Lambe, Fredrik Wärnberg, Jan Adolfsson, Tommy Fornander. Placental weight and mortality in premenopausal breast cancer by tumor characteristics. Breast Cancer Res Treat. 2013 Jan;137(1):297-305
Nagalla S., J W. Chou, M. C. Willingham, J. Ruiz, J. P. Vaughn, P. Dubey, T. L. Lash, S. J. Hamilton- Dutoit, J. Bergh, C. Sotiriou, M. A. Black, L. D. Miller. Interactions between Immunity, Proliferation and Molecular Subtype in Breast Cancer Prognosis. Genome Biology 14(4): R34, 2013.
Nemes S, Parris TZ, Danielsson A, Einbeigi Z, Steineck G, Jonasson JM, Helou K. Integrative genomics with mediation analysis in a survival context. Comput Math Methods Med. 2013; 2013:413783.
Olsson N, Carlsson P, James P, Hansson K, Waldemarson S, Malmstrom P, Ferno M, Ryden L, Wingren C, Borrebaeck CA: Grading breast cancer tissues using molecular portraits. Molecular & cellular proteomics : MCP 2013, 12(12):3612-3623.
Rissanen R, Arving C, Ahlgren J, Cernvall M, Nordin K. Cognitive processing in relation to psychological distress in women with breast cancer: a theoretical approach. Psychooncology. 2014 Feb;23(2):222-8. doi: 10.1002/pon.3392. Epub 2013 Sep 16.
Rosell J, Nordenskjold B, Bengtsson NO, Fornander T, Hatschek T, Lindman H, Malmstrom PO, Wallgren A, Stal O, Carstensen J: Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up. Breast Cancer Res Treat 2013, 138(2):467-473.
Rubio CA, Svane G, Ilescu G, Adalsteinsson B, Mathiesen T, Tholin M, Machida M, Cervantes EC, Mattsson L, Azavedo E: Pitfall in assessing the size of tumor phantoms on mammograms. Anticancer Res 2013, 33(3):1131-1134.
Sandberg ME, Alkner S, Hartman M, Eloranta S, Ryden L, Ploner A, Adami HO, Hall P, Czene K:
Influence of radiotherapy for the first tumor on aggressiveness of contralateral breast
cancer. Int J Cancer 2013, 132(10):2388-2394.
Sand-Dejmek J, Ehrnstrom R, Berglund P, Andersson T, Ryden L: The prognostic significance of Wnt-
5a expression in primary breast cancer is extended to premenopausal women. PLoS One
2013, 8(8):e70890.
Shenvi S, Kumar K, Hatti KS, Rijesh K, Diwakar L, Reddy GC: Synthesis, anticancer and antioxidant
activities of 2,4,5-trimethoxy chalcones and analogues from asaronaldehyde: structure-
activity relationship. European journal of medicinal chemistry 2013, 62:435-442.
Shubbar E, Helou K, Kovács A, Nemes S, Hajizadeh S, Enerbäck C, Einbeigi Z. High levels of γ-glutamyl
hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in
invasive breast cancer. BMC Cancer. 2013 Feb 1;13:47.
Shubbar E, Kovács A, Hajizadeh S, Parris TZ, Nemes S, Gunnarsdóttir K, Einbeigi Z, Karlsson P, Helou K.
Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable
clinical outcome. BMC Cancer. 2013 Jan 2;13:1.
Sjodahl G, Lovgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G, Aine M, Eriksson P, Mansson W,
Lindgren D et al: Toward a molecular pathologic classification of urothelial carcinoma. Am J
Pathol 2013, 183(3):681-691.
Strand C, Bak M, Borgquist S, Chebil G, Falck AK, Fjallskog ML, Grabau D, Hedenfalk I, Jirstrom K,
Klintman M et al: The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naive women with N0/N1 primary breast cancer. Springerplus 2013, 2(1):111.
Suzuki C, Blomqvist L, Hatschek T, Carlsson L, Einbeigi Z, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Söderberg M, Sundqvist M, Walz TM, Aström G, Fujii H, Jacobsson H, Glimelius B.: Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy. Med Oncol 2013, 30(1):415.
Taher C, de Boniface J, Mohammad AA, Religa P, Hartman J, Yaiw KC, Frisell J, Rahbar A, Soderberg- Naucler C: High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLoS One 2013, 8(2):e56795.
Thomson HJ, Winters ZE, Brandberg Y, Didier F, Blazeby JM, Mills J: The early development phases of a European Organisation for Research and Treatment of Cancer (EORTC) module to assess patient reported outcomes (PROs) in women undergoing breast reconstruction. Eur J Cancer 2013, 49(5):1018-1026.
Walters S, Maringe C, Butler J, Rachet B, Barrett-Lee P, Bergh J, Boyages J, Christiansen P, Lee M, Wärnberg F, Allemani C, Engholm G, Fornander T, Gjerstorff ML, Johannesen TB, Lawrence G, McGahan CE, Middleton R, Steward J, Tracey E, Turner D, Richards MA, Coleman MP. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. Br J Cancer. 2013 Mar 19;108(5):1195-208
Weiner M, Skoog L, Fornander T, Nordenskjold B, Sgroi DC, Stal O: Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013, 24(8):1994- 1999.
Zhang Y, Schnabel CA, Schroeder BE, Jerevall PL, Jankowitz RC, Fornander T, Stal O, Brufsky AM, Sgroi D, Erlander MG: Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. Clin Cancer Res 2013, 19(15):4196-4205.
Zhou W, Jirstrom K, Amini RM, Fjallskog ML, Sollie T, Lindman H, Sorlie T, Blomqvist C, Warnberg F:
Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. BMC Cancer 2013, 13:512.
Zhou W, Johansson C, Jirström K, Ringberg A, Blomqvist C, Amini RM, Fjällskog ML, Wärnberg F.
Tumor Markers Predicting Type of Recurrence after a Primary Ductal Carcinoma In Situ. Int J Breast Cancer. 2013;2013:582134. Epub 2013 Dec 29.
2012
Allemani C, Sant M, Weir HK, Richardson LC, Baili P, Storm H, Siesling S, Torrella-Ramos A, Voogd AC, Aareleid T, Ardanaz E, Berrino F, Bielska-Lasota M, Bolick S, Cirilli C, Colonna M, Contiero P, Cress R, Crocetti E, Fulton JP, Grosclaude P, Hakulinen T, Izarzugaza MI, Malmstrom P, Peignaux K, Primic-Zakelj M, Rachtan J, Safaei Diba C, Sanchez MJ, Schymura MJ, Shen T, Traina A, Tryggvadottir L, Tumino R, Velten M, Vercelli M, Wolf HJ, Woronoff AS, Wu X, Coleman MP: Breast cancer survival in the US and Europe: A CONCORD high-resolution study. International journal of cancer Journal international du cancer 2012.
Andersson Y, de Boniface J, Jonsson PE, Ingvar C, Liljegren G, Bergkvist L, Frisell J: Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer. The British journal of surgery 2012, 99(2):226-231.
Andersson Y, Frisell J, de Boniface J, Bergkvist L: Prediction of non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastases: evaluation of the tenon score. Breast cancer : basic and clinical research 2012, 6:31-38.
Armuand, G.M., K.A. Rodriguez-Wallberg, L. Wettergren, J. Ahlgren, G. Enblad, M. Hoglund, and C. Lampic, Sex differences in fertility-related information received by young adult cancer survivors. J Clin Oncol, 2012. 30(17): p. 2147-53.
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M: Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379(9816):633-640.
Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C: First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012, 30(9):921-929.
Bergh J, Jonsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattstrom D, Lindemann JP, Wiklund F, Henriksson R: FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012, 30(16):1919-1925.
Bergh J, Mariani G, Cardoso F, Liljegren A, Awada A, Vigano L, Huang X, Verkh L, Kern KA, Giorgetti C, Gianni L: Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast 2012, 21(4):507-513.
Bergh, J., I.M. Bondarenko, M.R. Lichinitser, A. Liljegren, R. Greil, N.L. Voytko, A.N. Makhson, J. Cortes, A. Lortholary, J. Bischoff, A. Chan, S. Delaloge, X. Huang, K.A. Kern, and C. Giorgetti, First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol, 2012. 30(9): p. 921-9.
Bergh, J., P.E. Jonsson, E.K. Lidbrink, M. Trudeau, W. Eiermann, D. Brattstrom, J.P. Lindemann, F. Wiklund, and R. Henriksson, FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol, 2012. 30(16): p. 1919-25.
Berglund, A., A. Wigertz, J. Adolfsson, J. Ahlgren, T. Fornander, F. Warnberg, and M. Lambe, Impact of comorbidity on management and mortality in women diagnosed with breast cancer. Breast Cancer Res Treat, 2012. 135(1): p. 281-9.
Bjorneklett HG, Lindemalm C, Rosenblad A, Ojutkangas ML, Letocha H, Strang P, Bergkvist L: A randomised controlled trial of support group intervention after breast cancer treatment: results on anxiety and depression. Acta oncologica 2012, 51(2):198-207.
Brandberg Y, Arver B, Johansson H, Wickman M, Sandelin K, Liljegren A. Less correspondence between expectations before and cosmetic results after risk-reducing mastectomy in women who are mutation carriers: A prospective study. Eur J Surg Oncol. 2012; 38: 38-43.
Brennan DJ, O’Connor DP, Laursen H, McGee SF, McCarthy S, Zagozdzon R, Rexhepaj E, Culhane AC, Martin FM, Duffy MJ, Landberg G, Ryden L, Hewitt SM, Kuhar MJ, Bernards R, Millikan RC, Crown JP, Jirstrom K, Gallagher WM: The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERalpha, and is an independent prognostic factor in node-negative breast cancer. Oncogene 2012, 31(30):3483-3494.
Busch, S., L. Ryden, O. Stal, K. Jirstrom, and G. Landberg, Low ERK phosphorylation in cancer- associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer. PLoS One, 2012. 7(9): p. e45669.
Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van’t Veer L, Viale G, Krop I, Winer E: 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21(3):242-252.
Chirgwin J, Sun Z, Smith I, Price KN, Thurlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS: The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast cancer research and treatment 2012, 131(1):295-306.
Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G: Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast 2012, 21(1):20-26.
Eriksson L, Hall P, Czene K, Dos Santos Silva I, McCormack V, Bergh J, Bjohle J, Ploner A: Mammographic density and molecular subtypes of breast cancer. British journal of cancer 2012, 107(1):18-23.
Eschrich, S.A., W.J. Fulp, Y. Pawitan, J.A. Foekens, M. Smid, J.W. Martens, M. Echevarria, V. Kamath, J.H. Lee, E.E. Harris, J. Bergh, and J.F. Torres-Roca, Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res, 2012. 18(18): p. 5134-43.
Falck, A.K., P.O. Bendahl, C. Ingvar, J. Isola, P.E. Jonsson, P. Lindblom, K. Lovgren, K. Rennstam, M. Ferno, and L. Ryden, Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study. BMC Cancer, 2012. 12: p. 403.
Harris HR, Bergkvist L, Wolk A: Alcohol intake and mortality among women with invasive breast cancer. British journal of cancer 2012, 106(3):592-595.
Harris HR, Bergkvist L, Wolk A: Coffee and black tea consumption and breast cancer mortality in a cohort of Swedish women. British journal of cancer 2012, 107(5):874-878.
Harris HR, Bergkvist L, Wolk A: Folate intake and breast cancer mortality in a cohort of Swedish women. Breast cancer research and treatment 2012, 132(1):243-250.
Harris HR, Bergkvist L, Wolk A: Selenium intake and breast cancer mortality in a cohort of Swedish women. Breast cancer research and treatment 2012, 134(3):1269-1277.
Hatschek T, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Soderberg M, Sundquist M, Walz TM, Hellstrom M, Svensson H, Astrom G, Brandberg Y, Carstensen J, Ferno M, Bergh J: Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. Breast cancer research and treatment 2012, 131(3):939-947.
Holm K, Grabau D, Lovgren K, Aradottir S, Gruvberger-Saal S, Howlin J, Saal LH, Ethier SP, Bendahl PO, Stal O, Malmstrom P, Ferno M, Ryden L, Hegardt C, Borg A, Ringner M: Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol 2012, 6(5):494- 506.
Hoyer M, Nordin K, Ahlgren J, Bergkvist L, Lambe M, Johansson B, Lampic C: Change in working time in a population-based cohort of patients with breast cancer. J Clin Oncol 2012, 30(23):2853- 2860.
Joensuu, H., P.L. Kellokumpu-Lehtinen, R. Huovinen, A. Jukkola-Vuorinen, M. Tanner, R. Kokko, J. Ahlgren, P. Auvinen, O. Paija, L. Helle, K. Villman, P. Nyandoto, G. Nilsson, M. Pajunen, R. Asola, P. Poikonen, M. Leinonen, V. Kataja, P. Bono, and H. Lindman, Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol, 2012. 30(1): p. 11-8.
Johansson, I., K.E. Aaltonen, A. Ebbesson, D. Grabau, C. Wigerup, I. Hedenfalk, and L. Ryden, Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis. Genes Chromosomes Cancer, 2012. 51(4): p. 375-83.
Jonsson B, Bergh J: Hurdles in anticancer drug development from a regulatory perspective. Nat Rev Clin Oncol 2012, 9(4):236-243.
Jonsson G, Staaf J, Vallon-Christersson J, Ringner M, Gruvberger-Saal SK, Saal LH, Holm K, Hegardt C, Arason A, Fagerholm R, Persson C, Grabau D, Johnsson E, Lovgren K, Magnusson L, Heikkila P, Agnarsson BA, Johannsson OT, Malmstrom P, Ferno M, Olsson H, Loman N, Nevanlinna H, Barkardottir RB, Borg A: The retinoblastoma gene undergoes rearrangements in BRCA1- deficient basal-like breast cancer. Cancer research 2012, 72(16):4028-4036.
Julin B, Wolk A, Bergkvist L, Bottai M, Akesson A: Dietary cadmium exposure and risk of postmenopausal breast cancer: a population-based prospective cohort study. Cancer research 2012, 72(6):1459-1466.
Kristensen, V.N., C.J. Vaske, J. Ursini-Siegel, P. Van Loo, S.H. Nordgard, R. Sachidanandam, T. Sorlie, F. Warnberg, V.D. Haakensen, A. Helland, B. Naume, C.M. Perou, D. Haussler, O.G. Troyanskaya, and A.L. Borresen-Dale, Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A, 2012. 109(8): p. 2802-7.
Lindemalm C, Granstam-Bjorneklett H, Bergkvist L, Ojutkangas ML, Strang P: Existential aspects are neglected in the evaluation of support-intervention in breast cancer patients. Acta oncologica 2012, 51(6):807-809.
Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J: Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012, 30(21):2601-2608.
Lundstedt D, Gustafsson M, Steineck G, Malmstrom P, Alsadius D, Sundberg A, Wilderang U, Holmberg E, Johansson KA, Karlsson P: Risk factors of developing long-lasting breast pain after breast cancer radiotherapy. International journal of radiation oncology, biology, physics 2012, 83(1):71-78.
Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ: Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. The lancet oncology 2012, 13(4):420-432.
Nagalingam A, Tighiouart M, Ryden L, Joseph L, Landberg G, Saxena NK, Sharma D: Med1 plays a critical role in the development of tamoxifen resistance. Carcinogenesis 2012, 33(4):918- 930.
Nilsson C, Johansson I, Ahlin C, Thorstenson S, Amini RM, Holmqvist M, Bergkvist L, Hedenfalk I, Fjallskog ML: Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. Acta oncologica 2012.
Nilsson C, Koliadi A, Johansson I, Ahlin C, Thorstenson S, Bergkvist L, Hedenfalk I, Fjallskog ML: High proliferation is associated with inferior outcome in male breast cancer patients. Mod Pathol 2012.
Nordin, K., R. Rissanen, J. Ahlgren, G. Burell, M.L. Fjallskog, S. Borjesson, and C. Arving, Design of the study: how can health care help female breast cancer patients reduce their stress symptoms? A randomized intervention study with stepped-care. BMC Cancer, 2012. 12: p. 167.
Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K: Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379(9814):432-444.
Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM: Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012, 23(11):2866-2873.
Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thurlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J: Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. British journal of cancer 2012, 106(10):1618-1625.
Rosin G, Hannelius U, Lindstrom L, Hall P, Bergh J, Hartman J, Kere J: The dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer. BMC Cancer 2012, 12:79.
Sandberg ME, Alkner S, Hartman M, Eloranta S, Ryden L, Ploner A, Adami HO, Hall P, Czene K:
Influence of radiotherapy for the first tumor on aggressiveness of contralateral breast
cancer. International journal of cancer Journal international du cancer 2012.
Steven A. Eschrich,, William J.Fulp, M.S., Yudi Pawitan, John Foekens, MD, Marcel Smid, Michelle
Echevarria, M.S., Vidya Kamath, Ph.D.,Ji-Hyun Lee, Eleanor E. Harris, Jonas Bergh, and Javier F. Torres-Roca, Validation of a Radiosensitivity in Molecular Signature in Breast Cancer. Clin Cancer Res 18:5134-43, 2012.
Strand, C., C. Ahlin, P.O. Bendahl, M.L. Fjallskog, I. Hedenfalk, P. Malmstrom, and M Ferno,
Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer. Breast Cancer Res Treat, 2012. 131(1): p. 33-40.
Unukovych D, Sandelin K, Liljegren A, Arver B, Wickman M, Johansson H, Brandberg Y. Contralateral prophylactic mastectomy in breast cancer patients with a family history: a prospective 2- years follow-up study of health related quality of life, sexuality and body image. Eur J Cancer. 2012; 48: 3150-3156.
Unukovych D, Sandelin K, Wickman M, Arver B, Johansson H, Brandberg Y, Liljegren A. Breast reconstruction in patients with personal and family history of breast cancer undergoing contralateral prophylactic mastectomy, a 10-year experience. Acta Oncol. 2012; 51: 934- 941.
Vichapat V, Garmo H, Holmqvist M, Liljegren G, Warnberg F, Lambe M, Fornander T, Adolfsson J, Luchtenborg M, Holmberg L: Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. J Clin Oncol 2012, 30(28):3478-3485.
Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff R, Rimm DL: Cytoplasmic estrogen receptor in breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2012, 18(1):118-126.
Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, Bergkvist L, Lambe M:
Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast cancer research and treatment 2012, 133(1):367-373.
2011
Alkner S, Bendahl PO, Ferno M, Manjer J, Ryden L: Prediction of outcome after diagnosis of metachronous contralateral breast cancer. BMC Cancer 2011, 11:114.
Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Jensen AB, Karlsson P, Tange UB, Sorensen PG, Moller S et al: Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011, 29(3):264-271.
Arver B, Isaksson K, Atterhem H, Baan A, Bergkvist L, Brandberg Y, Ehrencrona H, Emanuelsson M, Hellborg H, Henriksson K, Karlsson P, Loman N, Lundberg J, Ringberg A, Askmalm MS, Wickman M, Sandelin K: Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey. Annals of surgery 2011, 253(6):1147-1154.
Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roche H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T: High- dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 2011, 29(24):3214-3223.
Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E et al: TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011, 12(6):527-539.
Brennan DJ, Laursen H, O’Connor DP, Borgquist S, Uhlen M, Gallagher WM, Ponten F, Millikan RC, Ryden L, Jirstrom K: Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen. Breast Cancer Res 2011, 13(1):R12.
Campa D, Claus R, Dostal L, Stein A, Chang-Claude J, Meidtner K, Boeing H, Olsen A, Tjonneland A, Overvad K et al: Variation in genes coding for AMP-activated protein kinase (AMPK) and breast cancer risk in the European Prospective Investigation on Cancer (EPIC). Breast Cancer Res Treat 2011.
Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J et al: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995- 2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011, 377(9760):127-138.
Cserni G, Amendoeira I, Bianchi S, Chmielik E, Degaetano J, Faverly D, Figueiredo P, Foschini MP, Grabau D, Jacquemier J et al: Distinction of isolated tumour cells and micrometastasis in lymph nodes of breast cancer patients according to the new Tumour Node Metastasis (TNM) definitions. Eur J Cancer 2011, 47(6):887-894.
Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011, 378(9804):1707-1716.
Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378(9793):771-784.
Eaker S, Wigertz A, Lambert PC, Bergkvist L, Ahlgren J, Lambe M: Breast cancer, sickness absence, income and marital status. A study on life situation 1 year prior diagnosis compared to 3 and 5 years after diagnosis. PLoS One 2011, 6(3):e18040.
Edlund P, Ahlgren J, Bjerre K, Andersson M, Bergh J, Mouridsen H, Holmberg SB, Bengtsson NO, Jakobsen E, Moller S et al: Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. Acta Oncol 2011, 50(3):329-337.
Foukakis T, Fornander T, Lekberg T, Hellborg H, Adolfsson J, Bergh J: Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast cancer research and treatment 2011, 130(2):553-560.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ: Strategies for subtypes– dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22(8):1736-1747.
Hietala M, Henningson M, Ingvar C, Jonsson PE, Rose C, Jernstrom H: Natural remedy use in a prospective cohort of breast cancer patients in southern Sweden. Acta Oncol 2011, 50(1):134-143.
Hillmer AM, Yao F, Inaki K, Lee WH, Ariyaratne PN, Teo AS, Woo XY, Zhang Z, Zhao H, Ukil L, Chen JP, Zhu F, So JB, Salto-Tellez M, Poh WT, Zawack KF, Nagarajan N, Gao S, Li G, Kumar V, Lim HP, Sia YY, Chan CS, Leong ST, Neo SC, Choi PS, Thoreau H, Tan PB, Shahab A, Ruan X, Bergh J, Hall P, Cacheux-Rataboul V, Wei CL, Yeoh KG, Sung WK, Bourque G, Liu ET, Ruan Y: Comprehensive long-span paired-end-tag mapping reveals characteristic patterns of structural variations in epithelial cancer genomes. Genome Res 2011, 21(5):665-675.
Hoyer M, Johansson B, Nordin K, Bergkvist L, Ahlgren J, Lidin-Lindqvist A, Lambe M, Lampic C: Health- related quality of life among women with breast cancer – a population-based study. Acta oncologica 2011, 50(7):1015-1026.
Iiristo M, Wiklund T, Wilking N, Bergh J, Brandberg Y: Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels. Acta oncologica 2011, 50(3):338-343.
Inaki K, Hillmer AM, Ukil L, Yao F, Woo XY, Vardy LA, Zawack KF, Lee CW, Ariyaratne PN, Chan YS, Desai KV, Bergh J, Hall P, Putti TC, Ong WL, Shahab A, Cacheux-Rataboul V, Karuturi RK, Sung WK, Ruan X, Bourque G, Ruan Y, Liu ET: Transcriptional consequences of genomic structural aberrations in breast cancer. Genome Res 2011, 21(5):676-687.
Isern AE, Manjer J, Malina J, Loman N, Martensson T, Bofin A, Hagen AI, Tengrup I, Landberg G, Ringberg A: Risk of recurrence following delayed large flap reconstruction after mastectomy for breast cancer. Br J Surg 2011.
Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L, Zhang Y, Massacesi C, Sahmoud T, Gianni L: Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast cancer research and treatment 2011, 125(2):447-455.
Khoshnoud MR, Lofdahl B, Fohlin H, Fornander T, Stal O, Skoog L, Bergh J, Nordenskjold B:
Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen. Breast cancer research and treatment 2011, 126(2):421-430.
Lehn S, Ferno M, Jirstrom K, Ryden L, Landberg G: A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle 2011, 10(6):956-962.
Lundgren K, Tobin NP, Lehn S, Stal O, Ryden L, Jirstrom K, Landberg G: Stromal expression of beta- arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer. J Mol Diagn 2011, 13(3):340-351.
Margolin S, Bengtsson NO, Carlsson L, Edlund P, Hellstrom M, Karlsson P, Lidbrink E, Linderholm B, Lindman H, Malmstrom P et al: A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. Acta Oncol 2011, 50(1):35-41.
Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D’Agostino R, Jr., Torti SV, Torti FM: An iron regulatory gene signature predicts outcome in breast cancer. Cancer research 2011, 71(21):6728-6737.
Nilsson C, Holmqvist M, Bergkvist L, Hedenfalk I, Lambe M, Fjallskog ML: Similarities and differences in the characteristics and primary treatment of breast cancer in men and women – a population based study (Sweden). Acta oncologica 2011, 50(7):1083-1088.
Norenstedt S, Granath F, Ekbom A, Bergh J, Lambe M, Adolfsson J, Warnberg F, Zedenius J, Nilsson IL: Breast cancer associated with primary hyperparathyroidism: a nested case control study. Clin Epidemiol 2011, 3:103-106.
Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringner M, Vallon-Christersson J, Jonsson G, Holm K, Lovgren K, Ferno M, Grabau D, Borg A, Hegardt C: CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 2011, 11:418.
Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Lang I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thurlimann B: Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. The lancet oncology 2011, 12(12):1101-1108.
Regan MM, Price KN, Giobbie-Hurder A, Thurlimann B, Gelber RD: Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res 2011, 13(3):209.
Rosell J, Nordenskjold B, Bengtsson NO, Fornander T, Hatschek T, Lindman H, Malmstrom PO, Wallgren A, Stal O, Carstensen J: Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial. British journal of cancer 2011, 104(6):899-902.
Strand C, Ahlin C, Bendahl PO, Fjallskog ML, Hedenfalk I, Malmstrom P, Ferno M: Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer. Breast Cancer Res Treat 2011.
Svensson H, Hatschek T, Johansson H, Einbeigi Z, Brandberg Y: Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer. Med Oncol 2011.
Sverrisdottir A, Johansson H, Johansson U, Bergh J, Rotstein S, Rutqvist L, Fornander T: Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. Breast cancer research and treatment 2011, 128(3):755-763.
Wennmalm K, Bergh J: A simple method for assigning genomic grade to individual breast tumours. BMC Cancer 2011, 11:306.
Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, Johansson H, Lindstrom L, Bergh J: HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 2011, 125(2):553-561.
2010
Ahlin C, Ferno M, Amini RM, Tolockiene E, Blomqvist C, Bergh J, Fjallskog ML: [Ki-67 and cyclin A– prognostic factors in breast cancer. Time to introduce proliferation markers in clinical routine]. Lakartidningen 2010, 107(10):672-675.
Alkner S, Bendahl PO, Grabau D, Lovgren K, Stal O, Ryden L, Ferno M: AIB1 is a predictive factor for tamoxifen response in premenopausal women. Ann Oncol 2010, 21(2):238-244.
Andersson Y, Frisell J, Sylvan M, de Boniface J, Bergkvist L: Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. J Clin Oncol 2010, 28(17):2868-2873.
Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT et al: Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 2010, 70(23):9742-9754.
Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T et al: A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 2010, 42(10):885-892.
Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S: Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010, 2010(41):162-177.
Einbeigi Z, Enerback C, Wallgren A, Nordling M, Karlsson P: BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer – a population based study from the Western Sweden Health Care region. Acta Oncol 2010, 49(3):361-367.
Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, Cook M, Oliver C, Frost D, Mayes R et al: Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2010, 19(11):2859-2868.
Garcia-Caballero T, Grabau D, Green AR, Gregory J, Schad A, Kohlwes E, Ellis IO, Watts S, Mollerup J:
Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 2010, 56(4):472-480.
Howell A, Bergh J: Insights Into the Place of Fulvestrant for the Treatment of Advanced Endocrine Responsive Breast Cancer. Journal of Clinical Oncology 2010, 28(30):4548-4550.
Kallstrom AC, Salme R, Ryden L, Nordenskjold B, Jonsson PE, Stal O: 17ss-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer. Eur J Cancer 2010, 46(5):892-900.
Khoshnoud R, He Q, Sylvan M, Khoshnoud A, Ivarsson M, Fornander T, Bergh J, Frisell J, Rutqvist LE, Skog S: The impact of RNA standardization and heterogeneous gene expression on the results of cDNA array of human breast carcinoma. Int J Mol Med 2010, 25(5):735-741.
Klintman M, Bendahl PO, Grabau D, Lovgren K, Malmstrom P, Ferno M: The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol 2010, 23(2):251-259.
Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J et al: Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010, 28(12):2114-2122.
Lambe M, Wigertz A, Holmqvist M, Adolfsson J, Bardage C, Fornander T, Karlsson P, Odlind V, Persson I, Ahlgren J et al: Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. Breast Cancer Res Treat 2010, 121(3):679-683.
Lindström L, Howell S, Åström G, Wilking U, Lidbrink E, Armstrong A, Karlsson E, Hatschek T, Bergh J:
Controversies in the management of metastatic breast cancer: biologic evaluation of breast cancer – Should metastases be biopsised? ASCO Educational 2010.
Lundstedt D, Gustafsson M, Malmstrom P, Johansson KA, Alsadius D, Sundberg A, Wilderang U, Holmberg E, Anderson H, Steineck G et al: Symptoms 10-17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial. Radiother Oncol 2010, 97(2):281-287.
Malmstrom A, Hansen J, Malmberg L, Carlsson L, Svensson JH, Ahlgren J, Ahlin C, Jansson T, Westberg R: Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study. Acta Oncol 2010, 49(1):35-41.
Ofverholm A, Arkblad E, Skrtic S, Albertsson P, Shubbar E, Enerback C: Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene. Clin Biochem 2010, 43(3):331-334.
Paridaens RJ, Gelber S, Cole BF, Gelber RD, Thurlimann B, Price KN, Holmberg SB, Crivellari D, Coates AS, Goldhirsch A: Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen- receptor-positive breast cancer. Breast Cancer Res Treat 2010, 123(1):303-310.
Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Ryden L, Luts L, Bendahl PO, Hedenfalk I: Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer. Breast Cancer Res Treat 2010, 122(2):315-324.
Rennstam K, Ringberg A, Cunliffe HE, Olsson H, Landberg G, Hedenfalk I: Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. Genes Chromosomes Cancer 2010, 49(1):78-90.
Ryden L, Grabau D, Schaffner F, Jonsson PE, Ruf W, Belting M: Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. Int J Cancer 2010, 126(10):2330-2340.
Ryden L, Jirstrom K, Haglund M, Stal O, Ferno M: Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat 2010, 120(2):491-498.
Sackey H, Sandelin K, Frisell J, Wickman M, Brandberg Y: Ductal carcinoma in situ of the breast. Long-term follow-up of health-related quality of life, emotional reactions and body image. Eur J Surg Oncol 2010, 36(8):756-762.
Staaf J, Jonsson G, Ringner M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmstrom PO, Johannsson OT et al: High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 2010, 12(3):R25.
Staaf J, Ringner M, Vallon-Christersson J, Jonsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA et al: Identification of subtypes in human epidermal growth factor receptor 2–positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 2010, 28(11):1813-1820.
Stendahl M, Nilsson S, Wigerup C, Jirstrom K, Jonsson PE, Stal O, Landberg G: p27(Kip1) is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients. Int J Cancer 2010, 127(12):2851-2858.
Styring E, Fernebro J, Jonsson PE, Ehinger A, Engellau J, Rissler P, Rydholm A, Nilbert M, Vult von Steyern F: Changing clinical presentation of angiosarcomas after breast cancer: from late tumors in edematous arms to earlier tumors on the thoracic wall. Breast Cancer Res Treat 2010, 122(3):883-887.
Svensson H, Einbeigi Z, Johansson H, Hatschek T, Brandberg Y: Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine). Breast Cancer Res Treat 2010, 123(3):785-793.
Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376(9737):235-244.
Wilking U, Jonsson B, Wilking N, Bergh J: Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden. Acta Oncol 2010, 49(6):844-850.
2009
Alkner S, Bendahl PO, Ferno M, Nordenskjold B, Ryden L: Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. Eur J Cancer 2009, 45(14):2496-2502.
Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X et al: Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2009, 18(22):4442-4456.
Bergh J: Quo vadis with targeted drugs in the 21st century? J Clin Oncol 2009, 27(1):2-5. Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, Gelber RD, Green MD, Peccatori F, Cinieri S,
Aebi S et al: The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15- 95 after prolonged follow-up. Ann Oncol 2009, 20(8):1344-1351.
Eaker S, Halmin M, Bellocco R, Bergkvist L, Ahlgren J, Holmberg L, Lambe M: Social differences in breast cancer survival in relation to patient management within a National Health Care System (Sweden). Int J Cancer 2009, 124(1):180-187.
Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E et al: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009, 15(1):68-74.
Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H: Breast cancer in young women: poor survival despite intensive treatment. PLoS One 2009, 4(11):e7695.
Giobbie-Hurder A, Price KN, Gelber RD: Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials 2009, 6(3):272-287.
Holmberg L, Duffy SW, Yen AM, Tabar L, Vitak B, Nystrom L, Frisell J: Differences in endpoints between the Swedish W-E (two county) trial of mammographic screening and the Swedish overview: methodological consequences. J Med Screen 2009, 16(2):73-80.
Jernstrom H, Bageman E, Rose C, Jonsson PE, Ingvar C: CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. Br J Cancer 2009, 101(11):1817-1823.
Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Asola R, Kokko R, Ahlgren J, Auvinen P, Hemminki A et al: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol 2009, 10(12):1145-1151.
Johnatty SE, Couch FJ, Fredericksen Z, Tarrell R, Spurdle AB, Beesley J, Chen X, Gschwantler-Kaulich D, Singer CF, Fuerhauser C et al: No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res Treat 2009, 117(2):371-379.
Kenne Sarenmalm E, Oden A, Ohlen J, Gaston-Johansson F, Holmberg SB: Changes in health-related quality of life may predict recurrent breast cancer. Eur J Oncol Nurs 2009, 13(5):323-329.
Killander F, Anderson H, Ryden S, Moller T, Hafstrom LO, Malmstrom P: Efficient reduction of loco- regional recurrences but no effect on mortality twenty years after postmastectomy radiation in premenopausal women with stage II breast cancer – a randomized trial from the South Sweden Breast Cancer Group. Breast 2009, 18(5):309-315.
Koscielny S, Arriagada R, Adolfsson J, Fornander T, Bergh J: Impact of tumour size on axillary involvement and distant dissemination in breast cancer. Br J Cancer 2009, 101(6):902-907.
Larsson AM, Jirstrom K, Fredlund E, Nilsson S, Ryden L, Landberg G, Pahlman S: Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer. Clin Cancer Res 2009, 15(17):5552-5559.
Mansson E, Bergkvist L, Christenson G, Persson C, Warnberg F: Mammographic casting-type calcifications is not a prognostic factor in unifocal small invasive breast cancer: a population-based retrospective cohort study. J Surg Oncol 2009, 100(8):670-674.
Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thurlimann B, Paridaens R, Smith I, Mauriac L, Forbes JF, Price KN, Regan MM et al: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361(8):766-776.
Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X et al: Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). Br J Cancer 2009, 101(12):2048-2054.
Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J et al: Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 2009, 116(3):491-500.
Pagani O, Price KN, Gelber RD, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thurlimann B, Collins J, Fey MF, Coates AS et al: Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Res Treat 2009, 117(2):319-324.
Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thurlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ et al: Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009, 20(9):1489-1498.
Rosendahl M, Ahlgren J, Andersen J, Bergh J, Blomquist C, Lidbrink E, Lindman H, Mouridsen H, Bjerre K, Andersson M: The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study. Eur J Cancer 2009, 45(18):3198-3204.
Ryden L, Haglund M, Bendahl PO, Hatschek T, Kolaric A, Kovacs A, Olsson A, Olsson H, Strand C, Ferno M: Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: a national survey performed at pathology departments in Sweden. Acta Oncol 2009, 48(6):860-866.
Thurlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS et al: Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 2009, 113(1):137-144.
2008
Axelsson CK, Jonsson PE: Sentinel lymph node biopsy in operations for recurrent breast cancer. Eur J Surg Oncol 2008, 34(6):626-630.
Bergkvist L, de Boniface J, Jonsson PE, Ingvar C, Liljegren G, Frisell J: Axillary recurrence rate after negative sentinel node biopsy in breast cancer: three-year follow-up of the Swedish Multicenter Cohort Study. Ann Surg 2008, 247(1):150-156.
Berglund P, Stighall M, Jirstrom K, Ryden L, Ferno M, Nordenskjold B, Landberg G: Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern. J Clin Pathol 2008, 61(2):184-191.
Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard KI et al: Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008, 371(9606):29-40.
Dihge L, Bendahl PO, Grabau D, Isola J, Lovgren K, Ryden L, Ferno M: Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat 2008, 109(2):255-262.
Einbeigi Z, Bergstrom D, Hatschek T, Malmberg M: Paclitaxel, Epirubicin and Capecitabine (TEX) as first-line treatmnet for metastatic breast cancer: a pilot phase I/II feasibility study. Clinical Medicine Insights: Oncology 2008(2):533-538.
Ferno M, Haglund M, Bendahl PO, Olsson H, Ryden L: [Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor]. Lakartidningen 2008, 105(32-33):2181-2184.
Gianni L, Cole BF, Panzini I, Snyder R, Holmberg SB, Byrne M, Crivellari D, Colleoni M, Aebi S, Simoncini E et al: Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. Support Care Cancer 2008, 16(1):67-74.
Gruber G, Cole BF, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Thurlimann B, Simoncini E et al: Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol 2008, 19(8):1393-1401.
Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, Karlsson P, Anderson H, Emdin S: Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol 2008, 26(8):1247-1252.
Isern AE, Loman N, Malina J, Olsson H, Ringberg A: Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer. Eur J Surg Oncol 2008, 34(10):1148-1154.
Isern AE, Tengrup I, Loman N, Olsson H, Ringberg A: Aesthetic outcome, patient satisfaction, and health-related quality of life in women at high risk undergoing prophylactic mastectomy and immediate breast reconstruction. J Plast Reconstr Aesthet Surg 2008, 61(10):1177-1187.
Jerevall PL, Brommesson S, Strand C, Gruvberger-Saal S, Malmstrom P, Nordenskjold B, Wingren S, Soderkvist P, Ferno M, Stal O: Exploring the two-gene ratio in breast cancer – independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Research and Treatment 2008, 107(2):225-234.
Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, Cold S, Edlund P, Ewertz M, Kamby C et al: Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008, 47(4):740-746.
Linderholm BK, Gruvberger-Saal S, Ferno M, Bendahl PO, Malmstrom P: Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer. Breast 2008, 17(5):484- 491.
Nimeus-Malmstrom E, Krogh M, Malmstrom P, Strand C, Fredriksson I, Karlsson P, Nordenskjold B, Stal O, Ostberg G, Peterson C et al: Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy. Breast Cancer Res 2008, 10(2):R34.
Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thurlimann B et al: Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 2008, 26(18):3006-3014.
Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A et al: p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Ann Oncol 2008, 19(4):660-668.
Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thurlimann B, Maibach R et al: Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol 2008, 19(7):1231-1241.
Ryden L, Landberg G, Stal O, Nordenskjold B, Ferno M, Bendahl PO: HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Res Treat 2008, 109(2):351-357.
Svensson H, Brandberg Y, Einbeigi Z, Hatschek T, Ahlberg K: Psychological Reactions to Progression of Metastatic Breast Cancer-An Interview Study. Cancer Nurs 2008.
Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C et al: Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008, 26(34):5569-5575.
2007
Ahlqvist-Rastad J, Albertsson M, Bergh J, Birgegard G, Johansson P, Jonsson B, Kjellen E, Pahlman S, Zackrisson B, Osterborg A: Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations. Med Oncol 2007, 24(3):267-272.
Celebioglu F, Frisell J, Danielsson R, Bergkvist L: Sentinel node biopsy in non-palpable breast cancer and in patients with a previous diagnostic excision. Eur J Surg Oncol 2007, 33(3):276-280.
Celebioglu F, Perbeck L, Frisell J, Grondal E, Svensson L, Danielsson R: Lymph drainage studied by lymphoscintigraphy in the arms after sentinel node biopsy compared with axillary lymph node dissection following conservative breast cancer surgery. Acta Radiol 2007, 48(5):488- 495.
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I et al: Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369(9561):559-570.
Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d’Assignies MS et al: Strong time dependence of the 76-gene prognostic signature for node- negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007, 13(11):3207-3214.
Einbeigi Z, Bergman A, Meis-Kindblom JM, Flodin A, Bjursell C, Martinsson T, Kindblom LG, Wahlstrom J, Wallgren A, Nordling M et al: Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden. Fam Cancer 2007, 6(1):35-41.
Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Cold S, Edlund P, Ewertz M, Jensen BB, Kamby C, Nordenskjold B et al: Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 2007, 43(5):877-884.
Grabau D, Jensen MB, Rank F, Blichert-Toft M: Axillary lymph node micrometastases in invasive breast cancer: national figures on incidence and overall survival. APMIS 2007, 115(7):828- 837.
Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, Dickman PW, Hall P: Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 2007, 25(27):4210-4216.
Karlsson P, Cole BF, Price KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, Murray E, Lindtner J, Collins JP, Holmberg SB et al: The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. J Clin Oncol 2007, 25(15):2019-2026.
Kellokumpu-Lehtinen P, Bergh J, Salminen E, Wiklund T, Lehtinen S, Aronen P, Sintonen H: Cost- effectiveness of intensive adjuvant chemotherapy for high-risk breast cancer: is tailored and dose-escalated chemotherapy with growth factor support (GFS) more costly and less effective than marrow-supported high-dose chemotherapy – results from a randomized study. Acta Oncol 2007, 46(2):146-152.
Killander F, Anderson H, Ryden S, Moller T, Aspegren K, Ceberg J, Danewid C, Malmstrom P:
Radiotherapy and tamoxifen after mastectomy in postmenopausal women — 20 year follow-up of the South Sweden Breast Cancer Group randomised trial SSBCG II:I. Eur J Cancer 2007, 43(14):2100-2108.
Lindman H, Astrom G, Ahlgren J, Villman K, Blomqvist C, Nygren P, Bergh J: Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer. Acta Oncol 2007, 46(2):165-171.
Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA et al: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25(10):1239-1246.
Lundkvist J, Wilking N, Holmberg S, Jonsson L: Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat 2007, 102(3):289-299.
Ringberg A, Nordgren H, Thorstensson S, Idvall I, Garmo H, Granstrand B, Arnesson LG, Sandelin K, Wallgren A, Anderson H et al: Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast–results from the Swedish randomised trial. Eur J Cancer 2007, 43(2):291-298.
Ryden L, Chebil G, Sjostrom L, Pawlowski R, Jonsson PE: Determination of sentinel lymph node (SLN) status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumour cells: analysis of 174 patients after SLN biopsy. Eur J Surg Oncol 2007, 33(1):33-38.
Schule J, Frisell J, Ingvar C, Bergkvist L: Sentinel node biopsy for breast cancer larger than 3 cm in diameter. Br J Surg 2007, 94(8):948-951.
Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369(9555):29-36.
Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007, 25(25):3859-3865.
Villman K, Ohd JF, Lidbrink E, Malmberg L, Lindh B, Blomqvist C, Nordgren H, Bergh J, Bergstrom D, Ahlgren J: A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. Eur J Cancer 2007, 43(7):1153-1160.
von Wachenfeldt A, Lindblom A, Gronberg H, Einbeigi Z, Rosenquist R, Gardman C, Iselius L: A hypothesis-generating search for new genetic breast cancer syndromes–a national study in 803 Swedish families. Hered Cancer Clin Pract 2007, 5(1):17-24.
Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G et al: Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 2007, 18(4):694-700.
2006
Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, Ryden L, Gallagher WM, O’Brien SL: CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 2006, 12(21):6421-6431.
Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM, d’Assignies MS, Bergh J, Lidereau R, Ellis P et al: Validation and clinical utility of a 70-gene prognostic signature for women with node- negative breast cancer. J Natl Cancer Inst 2006, 98(17):1183-1192.
Celebioglu F, Sylvan M, Perbeck L, Bergkvist L, Frisell J: Intraoperative sentinel lymph node examination by frozen section, immunohistochemistry and imprint cytology during breast surgery–a prospective study. Eur J Cancer 2006, 42(5):617-620.
Eaker S, Dickman PW, Bergkvist L, Holmberg L: Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden. PLoS Med 2006, 3(3):e25.
Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf PW, Kamby C et al: Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol 2006, 24(31):4956-4962.
Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, Anderson H, Garmo H, Holmberg L, Wallgren A: SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 2006, 45(5):536-543.
Gianni L, Panzini I, Li S, Gelber RD, Collins J, Holmberg SB, Crivellari D, Castiglione-Gertsch M, Goldhirsch A, Coates AS et al: Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer 2006, 106(3):505-513.
Kronblad A, Jirstrom K, Ryden L, Nordenskjold B, Landberg G: Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer 2006, 118(10):2609-2616.
Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I et al: The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006, 12(4):1157-1167.
Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O et al: Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006, 17(6):935-944.
Ringberg A, Bageman E, Rose C, Ingvar C, Jernstrom H: Of cup and bra size: reply to a prospective study of breast size and premenopausal breast cancer incidence. Int J Cancer 2006, 119(9):2242-2243; author reply 2244.
Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard J, Price KN et al: Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol 2006, 24(3):337-344.
Stendahl M, Ryden L, Nordenskjold B, Jonsson PE, Landberg G, Jirstrom K: High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006, 12(15):4614-4618.
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B et al: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98(4):262-272.
Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmstrom P, Wilking N, Nilsson J, Bergh J: Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu- amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006, 24(16):2428-2436.
2005
Albain KS, de la Garza Salazar J, Pienkowski T, Aapro M, Bergh J, Caleffi M, Coleman R, Eiermann W, Icli F, Pegram M et al: Reducing the global breast cancer burden: the importance of patterns of care research. Clin Breast Cancer 2005, 6(5):412-420.
Bergman A, Flodin A, Engwall Y, Arkblad EL, Berg K, Einbeigi Z, Martinsson T, Wahlstrom J, Karlsson P, Nordling M: A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques. Fam Cancer 2005, 4(2):89-96.
Bergkvist L, Frisell J: Multicentre validation study of sentinel node biopsy for staging in breast cancer. Br J Surg 2005, 92(10):1221-1224.
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366(9503):2087-2106.
Colleoni M, Li S, Gelber RD, Coates AS, Castiglione-Gertsch M, Price KN, Lindtner J, Rudenstam CM, Crivellari D, Collins J et al: Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol 2005, 16(5):716-725.
Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam CM, Lindtner J, Erzen D, Snyder R, Collins J et al: Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience. J Clin Oncol 2005, 23(7):1390-1400.
Eaker S, Dickman PW, Hellstrom V, Zack MM, Ahlgren J, Holmberg L: Regional differences in breast cancer survival despite common guidelines. Cancer Epidemiol Biomarkers Prev 2005, 14(12):2914-2918.
(EBCTCG) EBCTCG: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717.
Gruber G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Golouh R, Collins J et al: Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. J Clin Oncol 2005, 23(28):7089-7097.
Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D, Adami HO, Hall P: Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol 2005, 6(6):377-382.
Holmberg SB: [Anti-hormone breast cancer treatment. Convincing trials do exist–we have to take up a stand now!]. Lakartidningen 2005, 102(41):2920-2921.
Jernstrom H, Loman N, Johannsson OT, Borg A, Olsson H: Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur J Cancer 2005, 41(15):2312-2320.
Jirstrom K, Ryden L, Anagnostaki L, Nordenskjold B, Stal O, Thorstenson S, Chebil G, Jonsson PE, Ferno M, Landberg G: Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol 2005, 58(11):1135-1142.
Jirstrom K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O, Landberg G: Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005, 65(17):8009-8016.
Kald BA, Boiesen P, Ronnow K, Jonsson PE, Bisgaard T: Preoperative assessment of small tumours in women with breast cancer. Scand J Surg 2005, 94(1):15-20.
Nordenskjold B, Rosell J, Rutqvist LE, Malmstrom PO, Bergh J, Bengtsson NO, Hatschek T, Wallgren A, Carstensen J: Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 2005, 97(21):1609-1610.
Poikonen P, Sjostrom J, Amini RM, Villman K, Ahlgren J, Blomqvist C: Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer. Br J Cancer 2005, 93(5):515-519.
Ryden L, Jirstrom K, Bendahl PO, Ferno M, Nordenskjold B, Stal O, Thorstenson S, Jonsson PE, Landberg G: Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 2005, 23(21):4695-4704.
Ryden L, Jonsson PE, Chebil G, Dufmats M, Ferno M, Jirstrom K, Kallstrom AC, Landberg G, Stal O, Thorstenson S et al: Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 2005, 41(2):256-264.
2004
Batista N, Perez-Manga G, Constenla M, Ruiz A, Carabantes F, Castellanos J, Gonzalez Baron M, Villman K, Soderberg M, Ahlgren J et al: Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Br J Cancer 2004, 90(9):1740-1746.
Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Erien D, Collins J et al: Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 2004, 15(6):875-884.
Bergkvist L, Liljegren G, Ahlgren J, Lidin A, Holmqvist M, Holmberg L: [Registries contribute to better breast cancer care]. Lakartidningen 2004, 101(34):2579-2581.
Dalberg K, Johansson H, Signomklao T, Rutqvist LE, Bergkvist L, Frisell J, Liljegren G, Ambre T, Sandelin K: A randomised study of axillary drainage and pectoral fascia preservation after mastectomy for breast cancer. Eur J Surg Oncol 2004, 30(6):602-609.
Holmberg L, Anderson H: HABITS (hormonal replacement therapy after breast cancer–is it safe?), a randomised comparison: trial stopped. Lancet 2004, 363(9407):453-455.
Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S, Holmberg L, Bergh J:
Overexpression of cyclin E protein is associated with specific mutation types in the p53
gene and poor survival in human breast cancer. Carcinogenesis 2004, 25(3):375-380. Lindqvist R, Alvegard TA, Jonsson PE, Stenbeck M: Hospital stay related to TNM-stage and the
surgical procedure in primary breast cancer. Acta Oncol 2004, 43(6):545-550.
Malander S, Ridderheim M, Masback A, Loman N, Kristoffersson U, Olsson H, Nilbert M, Borg A: One
in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a
prospective study in Southern Sweden. Eur J Cancer 2004, 40(3):422-428. Nilsson-Ihrfelt E, Fjallskog ML, Blomqvist C, Ahlgren J, Edlund P, Hansen J, Malmberg L, Villman K,
Andersson G: Breast cancer on the Internet: the quality of Swedish breast cancer websites.
Breast 2004, 13(5):376-382.
Ryden L, Boiesen P, Jonsson PE: Assessment of microvessel density in core needle biopsy specimen
in breast cancer. Anticancer Res 2004, 24(1):371-375.
Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Landberg G: Tumor specific VEGF-A and
VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 2004,
82(3):147-154.
Schule JM, Bergkvist L, Hakansson L, Gustafsson B, Hakansson A: CD28 expression in sentinel node
biopsies from breast cancer patients in comparison with CD3-zeta chain expression. J Transl Med 2004, 2(1):45.
2003
Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117-1130.
Baldetorp B, Bendahl PO, Ferno M, Stal O: Improved DNA flow cytometric, DNA ploidy, and S-phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines. Cytometry A 2003, 56(1):1-7.
Brandberg Y, Michelson H, Nilsson B, Bolund C, Erikstein B, Hietanen P, Kaasa S, Nilsson J, Wiklund T, Wilking N et al: Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401. J Clin Oncol 2003, 21(19):3659-3664.
Chebil G, Bendahl PO, Ferno M: Estrogen and progesterone receptor assay in paraffin-embedded breast cancer–reproducibility of assessment. Acta Oncol 2003, 42(1):43-47.
Chebil G, Bendahl PO, Idvall I, Ferno M: Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer–clinical associations and reasons for discrepancies. Acta Oncol 2003, 42(7):719-725.
Fredriksson I, Liljegren G, Palm-Sjovall M, Arnesson LG, Emdin SO, Fornander T, Lindgren A, Nordgren H, Idvall I, Holmqvist M et al: Risk factors for local recurrence after breast-conserving surgery. Br J Surg 2003, 90(9):1093-1102.
Loman N, Bladstrom A, Johannsson O, Borg A, Olsson H: Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res 2003, 5(6):R175-186.
Luoma ML, Hakamies-Blomqvist L, Sjostrom J, Pluzanska A, Ottoson S, Mouridsen H, Bengtsson NO, Bergh J, Malmstrom P, Valvere V et al: Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. Eur J Cancer 2003, 39(10):1370-1376.
Malmstrom P, Holmberg L, Anderson H, Mattsson J, Jonsson PE, Tennvall-Nittby L, Balldin G, Loven L, Svensson JH, Ingvar C et al: Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. Eur J Cancer 2003, 39(12):1690-1697.
Ryden L, Boiesen P, Jonsson PE: Decreased angiogenic activity in breast cancer in ever-users of oral contraceptive therapy–preliminary report. Anticancer Res 2003, 23(3C):2875-2878.
Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thurlimann B, Fey M, Werner ID et al: Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 2003, 21(7):1205-1213.
Wilczek B, Aspelin P, Bone B, Pegerfalk A, Frisell J, Danielsson R: Complementary use of scintimammography with 99m-Tc-MIBI to triple diagnostic procedure in palpable and non- palpable breast lesions. Acta Radiol 2003, 44(3):288-293.
2002
Ahlgren J, Holmberg L, Bergh J, Liljegren G: Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in operable breast cancer. Eur J Surg Oncol 2002, 28(2):97-102.
Andersson J, Linderholm B, Greim G, Lindh B, Lindman H, Tennvall J, Tennvall-Nittby L, Pettersson- Skold D, Sverrisdottir A, Soderberg M et al: A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in Sweden. Acta Oncol 2002, 41(3):276-281.
CollaborativeGrouponHormonalFactorsinBreastCancer: Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002, 360(9328):187-195.
Colleoni M, Litman HJ, Castiglione-Gertsch M, Sauerbrei W, Gelber RD, Bonetti M, Coates AS, Schumacher M, Bastert G, Rudenstam CM et al: Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 2002, 86(11):1705-1714.
Einbeigi Z, Meis-Kindblom JM, Kindblom LG, Wallgren A, Karlsson P: Clustering of individuals with both breast and ovarian cancer–a possible indicator of BRCA founder mutations. Acta Oncol 2002, 41(2):153-157.
Fredriksson I, Liljegren G, Arnesson LG, Emdin SO, Palm-Sjovall M, Fornander T, Holmqvist M, Holmberg L, Frisell J: Consequences of axillary recurrence after conservative breast surgery. Br J Surg 2002, 89(7):902-908.
Fredriksson I, Liljegren G, Arnesson LG, Emdin SO, Palm-Sjovall M, Fornander T, Holmqvist M, Holmberg L, Frisell J: Local recurrence in the breast after conservative surgery–a study of prognosis and prognostic factors in 391 women. Eur J Cancer 2002, 38(14):1860-1870.
Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW, Jr., Coates RJ, Liff JM, Talamini R, Chantarakul N et al: Alcohol, tobacco and breast cancer–collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002, 87(11):1234-1245.
Hernberg M, Virkkunen P, Maasilta P, Keyrilainen J, Blomqvist C, Bergh J, Wiklund T: Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study. Int J Radiat Oncol Biol Phys 2002, 52(1):128-136.
Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE: Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002, 359(9310):909-919.
Ryden L, Chebil G, Jonsson PE: Small bowel obstruction caused by intestinal metastases from undiagnosed breast cancer: report of two cases. Eur J Surg 2002, 168(11):648-650.
Schule J, Bergkvist L, Hakansson L, Gustafsson B, Hakansson A: Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients. Breast Cancer Res Treat 2002, 74(1):33-40.
Sjostrom J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstad B, Wist E, Valvere V et al: C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 2002, 38(4):535-542.
2001
Bergh J, Holmquist M: Who should not receive adjuvant chemotherapy? International databases. J Natl Cancer Inst Monogr 2001(30):103-108.
Bergh J, Jonsson PE, Glimelius B, Nygren P: A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001, 40(2-3):253-281.
Bergkvist L, Frisell J, Liljegren G, Celebioglu F, Damm S, Thorn M: Multicentre study of detection and false-negative rates in sentinel node biopsy for breast cancer. Br J Surg 2001, 88(12):1644- 1648.
Bergman A, Einbeigi Z, Olofsson U, Taib Z, Wallgren A, Karlsson P, Wahlstrom J, Martinsson T, Nordling M: The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J Hum Genet 2001, 9(10):787-793.
Colleoni M, Gelber S, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thurlimann B et al: Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol 2001, 19(21):4141-4149.
Einbeigi Z, Bergman A, Kindblom LG, Martinsson T, Meis-Kindblom JM, Nordling M, Suurkula M, Wahlstrom J, Wallgren A, Karlsson P: A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur J Cancer 2001, 37(15):1904-1909.
Fredriksson I, Liljegren G, Arnesson LG, Emdin SO, Palm-Sjovall M, Fornander T, Frisell J, Holmberg L: Time trends in the results of breast conservation in 4694 women. Eur J Cancer 2001, 37(12):1537-1544.
Frisell J, Bergqvist L, Liljegren G, Thorn M, Damm S, Rydman H, Danielsson R: Sentinel node in breast cancer–a Swedish pilot study of 75 patients. Eur J Surg 2001, 167(3):179-183.
Glimelius B, Bergh J, Brandt L, Brorsson B, Gunnars B, Hafstrom L, Haglund U, Hogberg T, Janunger KG, Jonsson PE et al: The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types–summary and conclusions. Acta Oncol 2001, 40(2-3):135-154.
Hakamies-Blomqvist L, Luoma ML, Sjostrom J, Pluzanska A, Sjodin M, Mouridsen H, Ostenstad B, Mjaaland I, Ottosson S, Bergh J et al: Timing of quality of life (QoL) assessments as a source of error in oncological trials. J Adv Nurs 2001, 35(5):709-716.
Hall KS, Wiklund T, Erikstein B, Holte H, Kvalheim G, Sommer HH, Andersen A, Skovlund E, Bergh J, Hall C: Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients. Breast Cancer Res Treat 2001, 67(3):235-244.
Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP et al: Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001, 344(8):539-548.
Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J: The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001, 61(5):2256-2260.
Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A: Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 2001, 93(16):1215-1223.
Malmstrom P, Bendahl PO, Boiesen P, Brunner N, Idvall I, Ferno M: S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J Clin Oncol 2001, 19(7):2010-2019.
Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brondum-Nielsen K, Gerdes AM, Moller P, Kristoffersson U, Olsson H et al: Functional analysis of BRCA1 C- terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 2001, 10(4):353-360.
Warnberg F, Bergh J, Zack M, Holmberg L: Risk factors for subsequent invasive breast cancer and breast cancer death after ductal carcinoma in situ: a population-based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 2001, 10(5):495-499.
2000
Arnesson LG, Ahlgren J: Omitting axillary surgery for low-risk breast cancer patients–a Swedish prospective cohort study. Acta Oncol 2000, 39(3):291-294.
Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G et al: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000, 356(9239):1384-1391.
Boiesen P, Bendahl PO, Anagnostaki L, Domanski H, Holm E, Idvall I, Johansson S, Ljungberg O, Ringberg A, Ostberg G et al: Histologic grading in breast cancer–reproducibility between seven pathologic departments. South Sweden Breast Cancer Group. Acta Oncol 2000, 39(1):41-45.
Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thurlimann B et al: Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 2000, 18(3):584-590.
Erselcan T, Kairemo KJ, Wiklund TA, Hernberg M, Blomqvist CP, Tenhunen M, Bergh J, Joensuu H:
Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy,
or CMF in breast cancer. Br J Cancer 2000, 82(4):777-781.
Ferno M, Stal O, Baldetorp B, Hatschek T, Kallstrom AC, Malmstrom P, Nordenskjold B, Ryden S:
Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S- phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat 2000, 59(1):69-76.
Larsson PA, Glimelius B, Jeppsson B, Jonsson PE, Malmberg M, Gustavsson B, Carlsson G, Svedberg M: A pharmacokinetic study of 5-FU/leucovorin and alpha-interferon in advanced cancer. Acta Oncol 2000, 39(1):59-63.
Loman N, Johannsson O, Bendahl P, Dahl N, Einbeigi Z, Gerdes A, Borg A, Olsson H: Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer 2000, 36(11):1365- 1373.
Ringberg A, Idvall I, Ferno M, Anderson H, Anagnostaki L, Boiesen P, Bondesson L, Holm E, Johansson S, Lindholm K et al: Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast. Eur J Surg Oncol 2000, 26(5):444-451.
Sjostrom J, Blomqvist C, Heikkila P, Boguslawski KV, Raisanen-Sokolowski A, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstadt B, Bergh J et al: Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 2000, 6(8):3103- 3110.
Stal O, Borg A, Ferno M, Kallstrom AC, Malmstrom P, Nordenskjold B: ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 2000, 11(12):1545-1550.